Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk

Scand Cardiovasc J. 2008 Feb;42(1):38-47. doi: 10.1080/14017430701466402.

Abstract

Objective: Oxygen-dependent changes in vascular diameters may be detrimental when the endothelium is dysfunctional.

Design: Endothelial responsiveness was evaluated by brachial ultrasound and flow-mediated/nitroglycerin-mediated dilation (FMD/NMD). FMD/NMD was investigated in males with increased risk of cardiovascular disease (mean age 44+/-2 years, n=10) and matched controls without risk factors (44+/-2 years, n=10). FMD/NMD was assessed during normoxia (21% O2, 79% N2), while inhaling hypoxic gas (12.5% O2, FMDHyp/NMD), and 100% O2 supplementation (FMDO2/NMD). In a second study we addressed the effect of lipid lowering. Twenty persons with cardiovascular risk (mean age 50+/-2 years) were treated with atorvastatin (80 mg/day) and FMD/NMD was measured during normoxia, hypoxia and oxygen supplementation before, after 1 day and 3 months.

Results: Oxygen supplementation evoked vasoconstriction, while FMDHyp/NMD was reduced compared to FMD/NMD. Atorvastatin significantly lowered total cholesterol, LDL cholesterol, and ADMA after 1 day of treatment, while triglycerides, ApoB and hsCRP were lowered after 3 months. Atorvastatin did not change FMD/NMD irrespective of oxygen tension.

Conclusion: Irrespective of risk factors or atorvastatin, hypoxia reduced endothelial vasodilation while oxygen supplementation evoked vasoconstriction.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adult
  • Atorvastatin
  • Brachial Artery / drug effects
  • Brachial Artery / physiopathology
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / prevention & control
  • Cholesterol / blood
  • Endothelium, Vascular / diagnostic imaging
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology*
  • Female
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / physiopathology
  • Hyperoxia / physiopathology
  • Hypoxia / physiopathology
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Nitroglycerin / administration & dosage
  • Oxygen / administration & dosage*
  • Pyrroles / therapeutic use*
  • Regional Blood Flow
  • Research Design
  • Risk Factors
  • Treatment Outcome
  • Triglycerides / blood
  • Ultrasonography
  • Vasoconstriction / drug effects*
  • Vasodilation / drug effects*
  • Vasodilator Agents / administration & dosage

Substances

  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins
  • Pyrroles
  • Triglycerides
  • Vasodilator Agents
  • Cholesterol
  • Atorvastatin
  • Nitroglycerin
  • Oxygen